Introduction
Immunoglobulin light chain (AL) amyloidosis is the most common form of systemic amyloidosis, accounting for approximately 70% of all subjects suffering from these diseases. 1 It is caused by a plasma cell clone that infiltrates the bone marrow by less than 10% in half of the patients. Despite its relatively small size, the clone can set off a devastating multi-organ damage caused by the monoclonal light chain. 2 The amyloidogenic light chain misfolds and aggregates, depositing in tissues in the form of amyloid fibrils. 3 All organs, except for the central nervous system, can be affected by this process, that leads to irreversible organ dysfunction and death if unrecognized or treated ineffectively. 3 In the last 15 years, we have made substantial progress in understanding the biology of the amyloid plasma cell clone and the mechanisms of organ damage. Moreover, with accurate prognostic stratification and response assessment based on biomarkers of clonal and organ disease, we have learnt to safely apply treatments originally developed for multiple myeloma, to the fragile patients with AL amyloidosis. 2 , 4 , 5 Nevertheless, the timely recognition and the appropriate treatment of patients with AL amyloidosis remains challenging even for hematologists who are expert in multiple myeloma. In this review, we summarize the current knowledge on the pathogenesis of AL amyloidosis, and we focus on the clinical management of patients with this disease.
The Amyloid Clone and Mechanisms of Organ Damage
Not only is the amyloidogenic clone usually smaller in size than that causing multiple myeloma, but it is characterized by a significant frequency of chromosomal abnormalities, that can affect treatment outcomes. The most frequent is t(11;14) translocation, observed in almost 50% of patients. 6 The presence of t(11;14) is associated with poorer outcome with bortezomib-based and immunomodulatory (IMiDs)-based therapy, even when cyclophosphamide is added. 7 , 8 The adverse impact of t(11;14) can be overcome by melphalan, administered orally or in autologous stem cell transplant. 9 , 10 Gain of 1q21 is less frequent in AL amyloidosis than in multiple myeloma, being found in less than 20% of patients. 6 Patients harboring this abnormality have poorer outcome when treated with oral melphalan/dexamethasone (MDex) without the addition of bortezomib. 11 Clonal plasma cells in AL amyloidosis have similar phenotypic and copy number alteration profiles as those found in multiple myeloma, but their gene expression profile is similar to that of normal plasma cells. 12 A genome-wide association study showed a shared genetic susceptibility between AL amyloidosis and multiple myeloma, but cyclin D1 was a more prominent driver in AL amyloidosis. 13 The plasma cells rely on the proteasome to cope with the proteotoxicity exerted by the misfolded, amyloidogenic light chains. 14 – 16 This makes the amyloid plasma cell clone keenly sensitive to proteasome inhibitors.
The light chain variable region gene and the gene family of the clone can, at least in part, explain the variable organ tropism of AL amyloidosis. Indeed, three V l genes, IGLV2–14 , IGVL6-57 , and IGLV3-1 contribute to encoding the majority of amyloidogenic l light chains. 17 – 19 The germline gene LV6-57 is common in AL amyloidosis while it is exceedingly rare in normal B-cells, and it is associated with renal involvement. 20 Usage of LV1-44 germline gene is linked to predominant cardiac involvement, whereas KV1-33 is associated with involvement of the liver. 21
Since cardiac involvement is the main determinant of survival, efforts have been focused on unveiling the mechanisms of cardiac dysfunction in AL amyloidosis. The observation of complete clinical recovery of patients after effective chemotherapy in the absence of significant reduction of amyloid deposits indicates that the mass action caused by the deposits is not the only, and possibly not the main, determinant of organ dysfunction in AL amyloidosis. The availability of cardiac biomarkers, particularly N-terminal pro-natriuretic peptide type B (NT-proBNP) as a measure of amyloid cardiac dysfunction, showed that the clinical severity of heart failure and patient survival is linked to changes in the concentration of the circulating amyloidogenic free light chains rather than to changes in the amyloid load. 22 – 24 Indeed, the infusion of light chain purified from the urine of patients with cardiac amyloidosis causes a rapid increase in end-diastolic pressure in isolated mouse hearts in a matter of few minutes, which is not observed with control light chains. 25 Exposing Caenorhabditis elegans, a worm whose pharynx pulses rhythmically and is considered an analog of the vertebrate heart, to light chains of patients with cardiac AL amyloidosis, but not to control light chains, reduces the rate of pharynx contraction. 26
Finally, the injection of light chains from patients with cardiac AL amyloidosis in the heart of zebrafish reduces the cardiac output and the lifespan of the fishes in the absence of amyloid deposits, which is not observed with control light chains. 27 Overall, this clinical and experimental evidence point to the toxicity exerted by the circulating precursor as the main cause of cardiac dysfunction in AL amyloidosis. 28 , 29
Clinical Presentation and Diagnosis
The clinical manifestations of AL amyloidosis depend on organ involvement ( Figure 1 ) but are rarely specific. Involvement of the soft tissues with macroglossia, periorbital purpura, submandibular gland swelling, and shoulder pad sign can easily trigger the diagnosis but are uncommon. More frequently, AL amyloidosis manifests with sign and symptoms resembling those of more common conditions of the elderly. Cardiac involvement (approximately 80% of patients) manifests with heart failure with preserved ejection fraction. Echocardiography is the cornerstone of the assessment of amyloid cardiomyopathy revealing increased ventricular wall thickness and granular sparkling. While ejection fraction is usually preserved until late stages of the disease, longitudinal strain, and midwall fractional shortening are often altered and have prognostic relevance. 30 , 31 Electrocardiogram usually shows low limb voltages in cardiac AL amyloidosis. Late gadolinium enhancement at cardiac magnetic resonance strongly points to the diagnosis of heart involvement; moreover, cardiac magnetic resonance can quantify the extracellular volume that may reflect the amyloid load. 32 The scintigraphy tracers developed for imaging the amyloid deposits in the brain of patients with Alzheimer disease, can identify cardiac amyloidosis and are promising tools for detecting and possibly quantitating amyloid deposits also in systemic amyloidoses. 33 The uptake of bone tracers in patients with AL amyloidosis is absent or moderate, differently from transthyretin cardiac amyloidosis, characterized by a strong uptake. This difference can be used to distinguish between the two forms. 34 Increased concentrations of NT-proBNP are found in 100% of patients with cardiac AL amyloidosis, and precede symptoms and imaging alterations, allowing diagnosis at very early stages. 22 , 35 The kidney is involved in two-thirds of patients with AL amyloidosis. The disease manifests with albuminuria, evolving in nephrotic syndrome and progressing to renal failure eventually leading to end-stage renal disease if unrecognized or ineffectively treated. Involvement of the liver is characterized by organ enlargement without scan defects and elevation of alkaline phosphatase. Peripheral neuropathy is axonal, predominantly sensory and centripetal. Involvement of the autonomic nervous system is common but usually asymptomatic, although it can often become manifest with inappropriate use of hypotensive drugs. It is characterized by postural hypotension that can be preceded by the “resolution” of a pre-existing hypertension, erection defects in males and disturbances in bowel movements. General symptoms, most commonly profound fatigue and malnutrition, often accompany more organ-specific manifestations.
These clinical manifestations are not only resembling those of more common conditions, but they are usually associated with advanced stages of the disease. All this, unfortunately, results in frequent diagnostic delays. A recent survey showed that 40% of patients with AL amyloidosis remain undiagnosed 1 year after the onset of symptoms. 36 Similar delays are also observed in patients who are performing regular follow-up for monoclonal gammopathy of undetermined significance (MGUS) under the supervision of hematologists. 37 This is because the classical workup of patients with MGUS does not include appropriate, sensitive tools for the detection of the onset of organ involvement. Thus, we advocated the inclusion of sensitive markers of cardiac (NT-proBNP) and renal (albuminuria) amyloidosis in the regular follow-up of patients with MGUS and abnormal free light chain (FLC) ratio. 35 , 38
Once amyloidosis is suspected, the diagnosis requires the demonstration of amyloid deposits in a biopsy. The abdominal fat aspirate is simple and minimally invasive, although its interpretation requires expertise. In combination with biopsy of the bone marrow stained with Congo red and/or biopsy of a minor salivary gland, it can yield a diagnostic sensitivity of approximately 90%, thus sparing organ biopsies. 39 – 41 Nevertheless, organ biopsies may need to be performed in subjects with strong clinical suspicion and negative fat, gland, and bone marrow. Typing of the amyloid deposits is mandatory, in order to avoid misdiagnosis between AL amyloidosis and other common forms of systemic amyloidosis (listed in Table 1 ), such as hereditary or wild-type (formerly senile) transthyretin amyloidosis, hereditary apolipoprotein AI amyloidosis, leucocyte chemotactic factor-2 amyloidosis, and amyloidosis reactive to chronic inflammation. Incorrect typing could lead to disastrous therapeutic errors. 42 – 44 Unfortunately, light microscopy immunohistochemistry and immunofluorescence with commercial antibodies, the most commonly available techniques, are unreliable to characterize amyloid deposits. 45 , 46 Thus, in most instances a reliable diagnosis requires referral of patients to specialized centers. Light microscopy immunohistochemistry can be reliably performed at referral centers using custom-made antibodies. 47 Immunoelectron microscopy with commercial antibodies can correctly identify the amyloid type in almost 100% of patients. 40 Mass spectrometry-based proteomics can be used on whole tissues or after laser capture microdissection to reliably type amyloid deposits. 48 , 49
Once the diagnosis and typing of AL amyloidosis have been established, the diagnostic workup is completed by assessing the burden and severity of clonal and organ disease, as summarized in Table 2 . Given the small size of the amyloid plasma cell clone, the combination immunofixation of both serum and urine with measurement of circulating free light chain is required to grant adequate sensitivity. 50 – 53 Assessment of organ involvement is based on biomarkers, electrocardiogram, and imaging studies.
Staging
The survival of patients with AL amyloidosis is exceedingly heterogeneous, depending on the severity of cardiac dysfunction at the time of diagnosis: while patients who are diagnosed late, at a stage when heart damage is very advanced and not amenable of improvement with treatment survive only a few weeks, patients without heart involvement can survive years even if they fail to respond to therapy. This extreme heterogeneity requires accurate prognostic stratification for establishing the best therapeutic approach, balancing treatment intensity and rapidity of action with patients’ frailty, as well as for comparing results of clinical trials. The Mayo Clinic group established a simple and reliable staging system based on NT-proBNP and cardiac troponins, which was then modified by European investigators ( Table 3 ). 54 , 55 This staging system is now the most widely used for clinical trial design and patient management. Besides heart involvement, clonal burden, assessed by bone marrow plasma cell (BMPC) infiltration or dFLC (difference between involved and uninvolved circulating free light chains) has an independent impact on survival. Patients with AL amyloidosis and BMPC infiltrate >10% have a more reduced survival, which is comparable to that of patients who have concomitant overt multiple myeloma. 56 Subjects who have a very low (<50 mg/L) dFLC level have a significantly better outcome across cardiac stages. 57 , 58 The Mayo Clinic group has incorporated the dFLC level in the cardiac staging system ( Table 3 ). 59 The severity of renal involvement does not directly affect patient’s survival, but impacts the quality of life and reduces the access to effective therapy. A staging system predicting progression to dialysis has been proposed and validated by European investigators ( Table 3 ). 60 Similarly to heart involvement, recognition and prompt treatment of renal AL amyloidosis at early stages can almost abolish the risk of progression to dialysis, while late diagnosis at advanced stages is associated with higher risk of progression.
Treatment
The complexity of AL amyloidosis, which is due to the unique coexistence of a clonal plasma cell disorder and dysfunction multiple vital organs, makes treatment of this disease a challenge even for hematologists who are experts in the field of multiple myeloma. Indeed, the availability of new drugs, directly targeting the amyloid deposits, will probably displace AL amyloidosis from the realm of exclusive hematologic therapy. The experience of treating physicians significantly impacts patients’ outcomes, 61 and very few recent prospective controlled studies exist to guide the therapeutic strategy. Thus, whenever possible, patients should be referred to specialized centers for treatment. Indeed, the amyloid clone requires treatment even if in the vast majority of cases it does not meet the criteria for treating multiple myeloma. 62 Moreover, differently from patients with multiple myeloma, subjects suffering from AL amyloidosis are at high risk of death and are extremely susceptible to treatment toxicity in the first few months after diagnosis; whereas, if they survive this first dangerous time, they enjoy a better long-term outcome compared to myeloma patients. 63 For this reason, chemotherapy is usually delivered at the lowest effective dose during the first cycles. The treatment strategy needs to be adapted to early treatment efficacy and should not be planned in advance. The response should frequently be assessed, at least every 2 cycles, in order to allow rapid switch to rescue therapy in patients who do not achieve satisfactory response. The criteria for hematologic, 57 , 58 , 64 cardiac, 64 and renal 60 response (summarized in Table 4 ) have been established and validated in a huge international effort and offer guidance to individual patients treatment, as well as surrogate endpoints for clinical trials. 65 In particular, a new criterion where both hematologic and organ response can be assessed simultaneously early on in the treatment of AL amyloidosis was proposed to stratify the risk of patients, supporting its use as a surrogate end-point in clinical trials. 66 In addition, a recent report from Mayo Clinic showed that the better survival was assessed in patients who obtained the deeper organs (heart, kidney, liver). 67
Chemotherapy targeting the amyloid plasma cell clone
Anti-plasma cell chemotherapy is the cornerstone of treatment of AL amyloidosis and was able to remarkably improve patients’ outcomes over the last decades. 5 Treatment of AL amyloidosis should be adapted to the severity of organ involvement.
Low-risk patients represent approximately 15% of all subjects suffering from AL amyloidosis and can be considered for autologous stem cell transplantation (ASCT). This procedure is associated with a substantially higher risk of early mortality compared to multiple myeloma. However, refinement in selection criteria has reduced transplant-related mortality over time. 61 Accumulation of expertise is also crucial, the outcome being significantly poorer at centers where less than four transplants per year are performed in patients with this disease. 61 When an adequate selection of transplant candidates is applied at referral centers, the outcome is excellent, with hematologic response in 71% of subjects and complete response (CR) in 35–37%. 61 , 68 These results in overall median survival of 7.6 years. 68 The great majority of transplant-related mortality occur in patients with elevated cardiac biomarkers, and subjects whose NT-proBNP is >5000 ng/L and/or cTnT is >0.06 ng/mL should not be offered ASCT. 69 , 70 Other eligibility criteria are ejection fraction >45% at echocardiography, New York Heart Association (NYHA) class <III, orthostatic systolic blood pressure >90 mmHg, age <65 years, performance status (Eastern Cooperative Oncology Group) ≤2, eGFR >50 mL/min per 1.73 m 2 unless on dialysis, and lung CO diffusion capacity >50%. 1 , 70 , 71 Patients who do not obtain CR after ASCT can receive bortezomib-based treatment. Overall, this sequential approach yields a 60% rate of CR. 72 Induction therapy with bortezomib before ASCT improves outcomes in patients with a bone marrow plasma cell infiltrate >10%. 73
Intermediate risk patients account for approximately 70% of patients with AL amyloidosis. They receive non-transplant chemotherapy. Until recently, a standard treatment for these patients has been oral melphalan and dexamethasone (MDex). 74 , 75 This regimen is very well tolerated and yields a 76% overall hematologic response rate, with CR in 31% of cases. 76 A randomized trial compared MDex to ASCT and failed to demonstrate an advantage for ASCT in terms of response rate and survival. 77 This trial was performed before the availability of a biomarker-based selection of transplant candidates, and the results were considered influenced by very high transplant-related mortality. Nevertheless, a landmark analysis excluding early deaths confirmed these results. Bortezomib-based regimens are now considered upfront standards of care in most patients with AL amyloidosis. A large retrospective study and a prospective trial showed efficacy of bortezomib in relapsed / refractory patients. 78 – 81 In the largest study of frontline treatment with cyclophosphamide, bortezomib and dexamethasone (CyBorD), the overall hematologic response rate was 60%, with CR in 23% of cases. 82 Two retrospective case-control studies showed higher response rates with bortezomib in combination with alkylating agents and dexamethasone compared to the previous standards of care MDex and cyclophosphamide / thalidomide / dexamethasone, though without a survival benefit. 83 , 84 An international phase III study ( NCT01277016 ) comparing MDex with bortezomib plus MDex (BMDex) has recently been completed, showing significantly higher overall hematologic response rate with BMDex (81% vs. 57%, P=0.005). 85 Based on this data, bortezomib should be offered to intermediate-risk patients, in the absence of contraindications such as peripheral neuropathy. The choice of the best combination should take into account clonal and patient characteristics. A recent study by Kastritis, et al. showed that addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib. 86 Treatment with BMDex has the advantage of overcoming the effects of both gain 1q21 (poor outcome with oral melphalan) and t(11;14) (poor outcome with bortezomib). 7 , 8 , 10 , 11 Oral melphalan should not reach the cumulative dose of 150 mg (not exceeding 2 cycles) in patients who may be selected for subsequent stem cell mobilization and harvest. 87 Treatment with bortezomib / dexamethasone alone or in combination with cyclophosphamide is preferred in patients with potentially reversible contraindication to ASCT, being stem cell sparing, as well as in subjects with renal failure.
The remaining 15–20% of patients with AL amyloidosis are high-risk, most frequently because of advanced cardiac stage (IIIb) or severe heart failure (NYHA class III or IV). So far, no treatment approach, including those based on bortezomib, was able to overcome the poor prognosis of these patients, and median survival ranges from 3 to 7 months. 88 Nevertheless, the few patients who survive long enough (at least 3 months) to take advantage of response to chemotherapy enjoy prolonged survival. 82 A recent report from The United Kingdom Group showed that patients achieving a rapid response at day 30 or overall CR/VGPR at 6 months had markedly better survival. 89 High-risk patients are treated with low-dose combinations, with weekly dose escalation based on tolerability under intensive monitoring. 1
Relapsed patients have a good prognosis, with remarkably longer survival than refractory subjects. 90 There is no consensus on criteria to start rescue therapy in relapsing subjects. 91 Cardiac progression should not be awaited, because it is associated with shorter survival. 90 Relapsing patients can be treated by repeating upfront therapy, if possible, although this is associated with shorter time to retreatment without reduction in overall survival. 92 When this is not possible, relapsed patients should be treated as subjects failing to respond to upfront therapy. A recent report defined that a potential role of deferred ASCT in both a consolidation or relapse setting in selected patients with cardiac AL who have achieved organ responses. 93 Immunemodulatory drugs (IMiDs) are the backbone of second-line therapy. Lenalidomide is able to overcome resistance to alkylating agents, proteasome inhibitors, and thalidomide. 94 – 99 However, this drug can cause worsening renal failure in patients with renal AL amyloidosis with significant proteinuria. 100 Lenalidomide combinations have been used also upfront with encouraging results. 97 , 98 , 101 – 104 Pomalidomide is one of the most powerful agents in refractory AL amyloidosis, being able to rescue patients refractory to alkylators, first- and second-generation proteasome inhibitors, and lenalidomide. 105 – 107 Hematologic response to pomalidomide is obtain rapidly, in a median time of 1 months, and is observed in more than 60% of patients. 107 Complete responses are relatively rare with IMiDs in pre-treated patients. However, the use of IMiDs could result in long progression-free intervals and survival rates among patients with AL amyloidosis. 108 Newer agents have been tested in the relapsed / refractory setting. The proteasome inhibitor carfilzomib yielded a hematologic response rate of 63% (CR 12%). 109 In this study, 39% of patients had NT-proBNP progression, which was clinically relevant in 18% of cases. The cardiac toxicity of carfilzomib is a cause of concern in AL amyloidosis. The oral proteasome inhibitor ixazomib proved active in per-treated patients, particularly in those who were not previously exposed to bortezomib, and is currently being tested in a randomized phase III trial in relapsed / refractory patients ( NCT01659658 ). 110 Thus, ixazomib seems particularly suitable for upfront combinations, allowing oral proteasome inhibitor-based regimens. Indeed, 2 trials of ixazomib, cyclophosphamide and dexamethasone ( NCT03236792 , NCT01864018 ) are ongoing in the upfront setting. Daratumumab is one of the most promising new agents for the treatment of patients with AL amyloidosis. A recently published series of previously treated subjects who received daratumumab reported a rapid (median 1 months) hematologic response in 76% of patients with 36% CRs. 111 In the 2017 American Society of hematology meeting, two different abstracts reported the preliminary data of prospective ongoing clinical trials about the use of daratumumab in relapse/refractory setting. 112 , 113 Daratumumab will likely be moved to upfront therapy in combination with proteasome inhibitor-based regimens in the near future. Indeed, a phase III randomized trial of daratumumab in combination with CyBorD vs. CyBorD alone in newly-diagnosed patients will be opened shortly ( NCT03201965 ).
Interfering with amyloidogenesis and organ damage and targeting the amyloid deposits
New, non-hematologic, approaches specifically targeting steps that are downstream in the pathogenic cascade are emerging as supplements of anti-plasma cell therapy, given in combination with chemotherapy or after achievement of hematologic response. Following the observation of the efficacy of the anthracycline 4′-iodo-4′-deoxy-doxorubicin on amyloidogenesis in vitro and reports of clinical improvements in subjects with AL amyloidosis, related non-cytotoxic and non-cardiotoxic compounds were investigated. 114 – 118 Amongst them, doxycycline was able to disrupt amyloid fibrils in transgenic mouse models of systemic amyloidosis, 119 , 120 and protected the C. elegans model from the effects of cardiotoxic amyloid light chains. 26 In a retrospective case-control study the administration of doxycycline as antibiotic prophylaxis during chemotherapy for AL amyloidosis reduced early mortality, resulting in higher response rates and survival improvement. 121 A phase III trial of chemotherapy with or without doxycycline is being designed. Polyphenols can redirect amyloidogenic polypeptides into unstructured, off-pathway oligomers. 122 Amongst them epigallocatechin-3-gallate was tested (EGCG) showed promising activity on cardiac AL amyloidosis in case reports and retrospective series. 123 – 125 In a phase II trial, EGCG was well tolerated and in some patients a decrease in albuminuria was observed. 126
The amyloid deposits are natural targets of novel therapies. United Kingdom investigators designed a compound CPHPC that avidly binds to serum amyloid P component (SAP) a protein that coats the amyloid fibrils protecting them from degradation. This compound is used to remove SAP from the bloodstream 127 before the administration of an anti-SAP antibody that promotes a complement-dependent, macrophage-derived reaction that removes visceral amyloid deposits. 128 This combination approach was tested in a pilot clinical study, 129 and a trial in patients with cardiac AL amyloidosis is ongoing ( NCT03044353 ). The report of the ability of this approach to induce organ response measured with validated criteria is eagerly awaited. Antibodies directly targeting the amyloid deposits have also been developed. One of them, 11-1F4, has been tested in phase I clinical trial, showing promising organ response in an interim analysis. 130 Those data were recently updated at the last ASH meeting. 131 A different antibody, NEOD001 is currently in the most advanced stage of clinical development. In a phase I/II study in patients with AL amyloidosis who had completed chemotherapy, cardiac and renal response rates were 57% and 60%, respectively. 132 Organ response to NEOD001 was independent of rate and depth of previous hematologic response. 133 Two phase III randomized, placebo-controlled trials of NEOD001 combined with bortezomib-based chemotherapy in newly-diagnosed patients ( NCT02312206 ), and as single agent in subjects who completed chemotherapy ( NCT02632786 ) have recently completed enrollment and results are eagerly awaited.
Supportive therapy
Supportive treatment is vital in patients with AL amyloidosis, in order to sustain organ function while chemotherapy takes effect, and to improve quality of life. However, treatment of concomitant heart failure and nephrotic syndrome in patients who often have concomitant involvement of the autonomic nervous system is extremely complicated, and should be done under close supervisions of specialized cardiologists and nephrologists who have experience in the treatment of patients with systemic amyloidosis. In some patients, asymptomatic involvement of the autonomic nervous system 134 could lead to overt, often severe hypotension when treatment with angiotensin-converting enzyme inhibitors is established. This therapy should be considered with caution and at the lowest effective dose. The development of a significant peripheral edema requires diuretics associated with dietary sodium restriction. Patients weigh themselves daily, and diuretic dosing should be titrated accordingly. It should be kept in mind that in patients with heat involvement cardiac function is preload dependent and reduction of intravascular volume should be avoided. Patients with recurrent arrhythmic syncope may benefit from pacemaker implantation; whereas, the use of implantable ICD is controversial. Gabapentin or pregabalin can be used to control neuropathic pain and octreotide can control diarrhea. Nutritional status is also frequently compromised in AL amyloidosis, independently affecting quality of life assessment. 135 – 137 Nutritional counseling is effective in improving mental quality of life and is associated with better survival. 138 Cardiac and renal transplant can be considered in patients who attain CR but are dialysis dependent or have persistent, severe heart failure. Moreover, young patients with isolated, advanced cardiac involvement may be considered for heart transplant followed by effective chemotherapy aiming at rapidly achieving CR.
Conclusions
Despite the recent advances the management of AL amyloidosis remains highly challenging and characterized by still unmet needs. The appropriate management of AL amyloidosis requires 1) early diagnosis, 2) correct typing, 3) accurate risk stratification and effective therapy guided by frequent careful assessment of response. Early diagnosis lies in the hands of general hematologists who are responsible for the follow-up of patients with MGUS. The onset of cardiac and renal involvement by AL amyloidosis in these subjects can be detected at a pre-symptomatic stage with simple markers, albuminuria and NT-proBNP, that should be part of the follow-up panel of patients with MGUS and abnormal FLC ratio. Amyloid typing is mandatory but requires advanced technology that needs to be concentrated at referral centers. The lack of controlled prospective studies and the importance of a critical level of expertise in specific and supportive therapy, also requires referral of patients to specialized centers whenever possible. Coordinated national networks are vital in sharing knowledge at rendering it accessible to patients. In the near future, the availability of newer powerful anti-plasma cell drugs, combined with anti-amyloid agent will hopefully further improve the outcome of patients with AL amyloidosis. Still clinical practice and research cannot be disconnected in this complex and dreadful disease.
Competing interests: The authors have declared that no competing interests exist.
References
1 Palladini G Merlini G What is new in diagnosis and management of light chain amyloidosis? Blood 2016 128 2 159 168 https://doi.org/10.1182/blood-2016-01-629790 27053535 10.1182/blood-2016-01-629790
2 Merlini G Stone M Dangerous small B-cell clones Blood 2006 108 8 2520 2530 https://doi.org/10.1182/blood-2006-03-001164 16794250 10.1182/blood-2006-03-001164
3 Merlini G AL amyloidosis: from molecular mechanisms to targeted therapies Hematology Am Soc Hematol Educ Program 2017 2017 1 1 12 29222231 10.1182/asheducation-2017.1.1 PMC6142527
4 Wechalekar AD Gillmore JD Hawkins PN Systemic amyloidosis Lancet 2016 387 10038 2641 2654 https://doi.org/10.1016/S0140-6736(15)01274-X 26719234 10.1016/S0140-6736(15)01274-X
5 Muchtar E Gertz MA Kumar SK Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death Blood 2017 129 15 2111 2119 https://doi.org/10.1182/blood-2016-11-751628 28126928 10.1182/blood-2016-11-751628 PMC5391625
6 Bochtler T Hegenbart U Cremer F Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability Blood 2008 111 9 4700 4705 https://doi.org/10.1182/blood-2007-11-122101 18305218 10.1182/blood-2007-11-122101
7 Bochtler T Hegenbart U Kunz C Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens J Clin Oncol 2015 33 12 1371 1378 https://doi.org/10.1200/JCO.2014.57.4947 25779559 10.1200/JCO.2014.57.4947
8 Muchtar E Dispenzieri A Kumar SK Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category Leukemia 2017 31 7 1562 1569 https://doi.org/10.1038/leu.2016.369 27904139 10.1038/leu.2016.369
9 Muchtar E Dispenzieri A Kumar SK Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type Haematologica 2016 101 9 1102 1109 https://doi.org/10.3324/haematol.2016.147041 27479823 10.3324/haematol.2016.147041 PMC5060027
10 Bochtler T Hegenbart U Kunz C Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study Blood 2016 128 4 594 602 https://doi.org/10.1182/blood-2015-10-676361 27257181 10.1182/blood-2015-10-676361
11 Bochtler T Hegenbart U Kunz C Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone Amyloid 2014 21 1 9 17 https://doi.org/10.3109/13506129.2013.854766 24455967 10.3109/13506129.2013.854766
12 Paiva B Martinez-Lopez J Corchete LA Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis Blood 2016 127 24 3035 3039 https://doi.org/10.1182/blood-2015-10-673095 27069257 10.1182/blood-2015-10-673095
13 da Silva Filho MI Försti A Weinhold N Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma Leukemia 2017 31 8 1735 1742 https://doi.org/10.1038/leu.2016.387 28025584 10.1038/leu.2016.387
14 Sitia R Palladini G Merlini G Bortezomib in the treatment of AL amyloidosis: targeted therapy? Haematologica 2007 92 10 1302 1307 https://doi.org/10.3324/haematol.12136 18024367 10.3324/haematol.12136
15 Bianchi G Oliva L Cascio P The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition Blood 2009 113 13 3040 3049 https://doi.org/10.1182/blood-2008-08-172734 19164601 10.1182/blood-2008-08-172734
16 Oliva L Orfanelli U Resnati M The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity Blood 2017 129 15 2132 2142 https://doi.org/10.1182/blood-2016-08-730978 28130214 10.1182/blood-2016-08-730978
17 Comenzo R Zhang Y Martinez C Osman K Herrera G The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden Blood 2001 98 3 714 720 https://doi.org/10.1182/blood.V98.3.714 11468171 10.1182/blood.v98.3.714
18 Perfetti V Casarini S Palladini G Analysis of V(lambda)-J(lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambdaIII) as a new amyloid-associated germline gene segment Blood 2002 100 3 948 953 https://doi.org/10.1182/blood-2002-01-0114 12130507 10.1182/blood-2002-01-0114
19 Abraham R Geyer S Price-Troska T Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL) Blood 2003 101 10 3801 3808 https://doi.org/10.1182/blood-2002-09-2707 12515719 10.1182/blood-2002-09-2707
20 Kourelis TV Dasari S Theis JD Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry Blood 2017 129 3 299 306 https://doi.org/10.1182/blood-2016-10-743997 27856462 10.1182/blood-2016-10-743997
21 Perfetti V Palladini G Casarini S The repertoire of ? light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1–44 Blood 2012 119 1 144 150 https://doi.org/10.1182/blood-2011-05-355784 22067386 10.1182/blood-2011-05-355784
22 Palladini G Campana C Klersy C Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis Circulation 2003 107 19 2440 2445 https://doi.org/10.1161/01.CIR.0000068314.02595.B2 12719281 10.1161/01.CIR.0000068314.02595.B2
23 Palladini G Lavatelli F Russo P Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL Blood 2006 107 10 3854 3858 https://doi.org/10.1182/blood-2005-11-4385 16434487 10.1182/blood-2005-11-4385
24 Palladini G Barassi A Klersy C The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis Blood 2010 116 18 3426 3430 https://doi.org/10.1182/blood-2010-05-286567 20644111 10.1182/blood-2010-05-286567
25 Liao R Jain M Teller P Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts Circulation 2001 104 14 1594 1597 11581134
26 Diomede L Rognoni P Lavatelli F A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis Blood 2014 123 23 3543 3552 https://doi.org/10.1182/blood-2013-10-525634 24665135 10.1182/blood-2013-10-525634 PMC4047494
27 Mishra S Guan J Plovie E Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish Am J Physiol Heart Circ Physiol 2013 305 1 H95 103 https://doi.org/10.1152/ajpheart.00186.2013 23624626 10.1152/ajpheart.00186.2013 PMC3727100
28 Lavatelli F Imperlini E Orru S Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis FASEB J 2015 29 11 4614 4628 https://doi.org/10.1096/fj.15-272179 26220173 10.1096/fj.15-272179
29 Oberti L Rognoni P Barbiroli A Concurrent structural and biophysical traits link with immunoglobulin light chains amyloid propensity Sci Rep 2017 7 1 16809 https://doi.org/10.1038/s41598-017-16953-7 29196671 10.1038/s41598-017-16953-7 PMC5711917
30 Perlini S Salinaro F Musca F Prognostic value of depressed midwall systolic function in cardiac light-chain amyloidosis J Hypertens 2014 32 5 1121 1131 discussion 1131. https://doi.org/10.1097/HJH.0000000000000120 24509117 10.1097/HJH.0000000000000120
31 Buss SJ Emami M Mereles D Longitudinal left ventricular function for prediction of survival in systemic light-chain amyloidosis: incremental value compared with clinical and biochemical markers J Am Coll Cardiol 2012 60 12 1067 1076 https://doi.org/10.1016/j.jacc.2012.04.043 22883634 10.1016/j.jacc.2012.04.043
32 Fontana M Chung R Hawkins PN Moon JC Cardiovascular magnetic resonance for amyloidosis Heart Fail Rev 2015 20 2 133 144 https://doi.org/10.1007/s10741-014-9470-7 25549885 10.1007/s10741-014-9470-7
33 Park MA Padera RF Belanger A 18F-Florbetapir Binds Specifically to Myocardial Light Chain and Transthyretin Amyloid Deposits: Autoradiography Study Circ Cardiovasc Imaging 2015 8 8 https://doi.org/10.1161/CIRCIMAGING.114.002954 10.1161/CIRCIMAGING.114.002954 PMC4535193 26259579
34 Gillmore JD Maurer MS Falk RH Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis Circulation 2016 133 24 2404 2412 https://doi.org/10.1161/CIRCULATIONAHA.116.021612 27143678 10.1161/CIRCULATIONAHA.116.021612
35 Merlini G Palladini G Differential diagnosis of monoclonal gammopathy of undetermined significance Hematology Am Soc Hematol Educ Program 2012 2012 595 603 23233640 10.1182/asheducation-2012.1.595
36 Lousada I Comenzo RL Landau H Guthrie S Merlini G Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium Adv Ther 2015 32 10 920 928 https://doi.org/10.1007/s12325-015-0250-0 26498944 10.1007/s12325-015-0250-0 PMC4635176
37 Kourelis TV Kumar SK Go RS Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias Am J Hematol 2014 89 11 1051 1054 https://doi.org/10.1002/ajh.23827 25111004 10.1002/ajh.23827
38 Merlini G Wechalekar AD Palladini G Systemic light chain amyloidosis: an update for treating physicians Blood 2013 121 26 5124 5130 https://doi.org/10.1182/blood-2013-01-453001 23670179 10.1182/blood-2013-01-453001
39 Foli A Palladini G Caporali R The role of minor salivary gland biopsy in the diagnosis of systemic amyloidosis: results of a prospective study in 62 patients Amyloid 2011 18 Suppl 1 80 82 https://doi.org/10.3109/13506129.2011.574354029 21838441 10.3109/13506129.2011.574354029
40 Fernandez de Larrea C Verga L Morbini P A practical approach to the diagnosis of systemic amyloidoses Blood 2015 125 14 2239 2244 https://doi.org/10.1182/blood-2014-11-609883 25636337 10.1182/blood-2014-11-609883
41 Muchtar E Dispenzieri A Lacy MQ Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition Ann Med 2017 49 7 545 551 https://doi.org/10.1080/07853890.2017.1304649 28271734 10.1080/07853890.2017.1304649
42 Anesi E Palladini G Perfetti V Arbustini E Obici L Merlini G Therapeutic advances demand accurate typing of amyloid deposits Am J Med 2001 111 3 243 244 https://doi.org/10.1016/S0002-9343(01)00774-4 11545098 10.1016/s0002-9343(01)00774-4
43 Lachmann H Booth D Booth S Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis N Engl J Med 2002 346 23 1786 1791 https://doi.org/10.1056/NEJMoa013354 12050338 10.1056/NEJMoa013354
44 Comenzo R Zhou P Fleisher M Clark B Teruya-Feldstein J Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins Blood 2006 107 9 3489 3491 https://doi.org/10.1182/blood-2005-10-4148 16439680 10.1182/blood-2005-10-4148
45 Satoskar A Burdge K Cowden D Nadasdy G Hebert L Nadasdy T Typing of amyloidosis in renal biopsies: diagnostic pitfalls Arch Pathol Lab Med 2007 131 6 917 922 17550319 10.5858/2007-131-917-TOAIRB
46 Satoskar AA Efebera Y Hasan A Strong transthyretin immunostaining: potential pitfall in cardiac amyloid typing Am J Surg Pathol 2011 35 11 1685 1690 https://doi.org/10.1097/PAS.0b013e3182263d74 21945954 10.1097/PAS.0b013e3182263d74 PMC4061151
47 Schönland SO Hegenbart U Bochtler T Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients Blood 2012 119 2 488 493 https://doi.org/10.1182/blood-2011-06-358507 22106346 10.1182/blood-2011-06-358507
48 Vrana J Gamez J Madden B Theis J Bergen Hr Dogan A Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens Blood 2009 114 24 4957 4959 https://doi.org/10.1182/blood-2009-07-230722 19797517 10.1182/blood-2009-07-230722
49 Brambilla F Lavatelli F Di Silvestre D Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue Blood 2012 119 8 1844 1847 https://doi.org/10.1182/blood-2011-07-365510 21917755 10.1182/blood-2011-07-365510
50 Katzmann J Kyle R Benson J Screening panels for detection of monoclonal gammopathies Clin Chem 2009 55 8 1517 1522 https://doi.org/10.1373/clinchem.2009.126664 19520758 10.1373/clinchem.2009.126664 PMC3773468
51 Bochtler T Hegenbart U Heiss C Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis Haematologica 2008 93 3 459 462 https://doi.org/10.3324/haematol.11687 18287137 10.3324/haematol.11687
52 Palladini G Russo P Bosoni T Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine Clin Chem 2009 55 3 499 504 https://doi.org/10.1373/clinchem.2008.117143 19131635 10.1373/clinchem.2008.117143
53 Palladini G Jaccard A Milani P Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays Clin Chem Lab Med 2017 https://doi.org/10.1515/cclm-2016-1024 28343171 10.1515/cclm-2016-1024
54 Dispenzieri A Gertz M Kyle R Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis J Clin Oncol 2004 22 18 3751 3757 https://doi.org/10.1200/JCO.2004.03.029 15365071 10.1200/JCO.2004.03.029
55 Wechalekar AD Schonland SO Kastritis E A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis Blood 2013 121 17 3420 3427 https://doi.org/10.1182/blood-2012-12-473066 23479568 10.1182/blood-2012-12-473066
56 Kourelis TV Kumar SK Gertz MA Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis J Clin Oncol 2013 31 34 4319 4324 https://doi.org/10.1200/JCO.2013.50.8499 24145344 10.1200/JCO.2013.50.8499 PMC4881366
57 Dittrich T Bochtler T Kimmich C AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis Blood 2017 130 5 632 642 https://doi.org/10.1182/blood-2017-02-767475 28550043 10.1182/blood-2017-02-767475
58 Milani P Basset M Russo F Foli A Merlini G Palladini G Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome Blood 2017 130 5 625 631 https://doi.org/10.1182/blood-2017-02-767467 28546143 10.1182/blood-2017-02-767467
59 Kumar S Dispenzieri A Lacy MQ Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements J Clin Oncol 2012 30 9 989 995 https://doi.org/10.1200/JCO.2011.38.5724 22331953 10.1200/JCO.2011.38.5724 PMC3675680
60 Palladini G Hegenbart U Milani P A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis Blood 2014 124 15 2325 2332 https://doi.org/10.1182/blood-2014-04-570010 25115890 10.1182/blood-2014-04-570010
61 D’Souza A Dispenzieri A Wirk B Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study J Clin Oncol 2015 33 32 3741 3749 https://doi.org/10.1200/JCO.2015.62.4015 26371138 10.1200/JCO.2015.62.4015 PMC4737858
62 Rajkumar SV Dimopoulos MA Palumbo A International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma Lancet Oncol 2014 15 12 e538 e548 https://doi.org/10.1016/S1470-2045(14)70442-5 25439696 10.1016/S1470-2045(14)70442-5
63 Dispenzieri A Seenithamby K Lacy MQ Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center Bone Marrow Transplant 2013 48 10 1302 1307 https://doi.org/10.1038/bmt.2013.53 23604010 10.1038/bmt.2013.53
64 Palladini G Dispenzieri A Gertz MA New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes J Clin Oncol 2012 30 36 4541 4549 https://doi.org/10.1200/JCO.2011.37.7614 23091105 10.1200/JCO.2011.37.7614
65 Merlini G Lousada I Ando Y Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis Leukemia 2016 30 10 1979 1986 https://doi.org/10.1038/leu.2016.191 27416985 10.1038/leu.2016.191 PMC5056962
66 Sidana S Tandon N Dispenzieri A Gertz MA Buadi FK Lacy MQ Dingli D Fonder A Hayman SR Hobbs M Gonsalves WI Hwa YL Kapoor P Kyle RA Leung N Go RS Lust JA Russell SJ Zeldenrust SR Binder M Rajkumar SV Kumar SK Composite Organ and Hematologic Response Model Risk Stratifies Patients with Light Chain Amyloidosis Blood 2017 130 Suppl 1 3046
67 Muchtar E Dispenzieri A Lacy MQ Leung N Buadi FK Grogan M Hayman SR Kapoor P Hwa YL Fonder A Hobbs M Chakraborty R Gonsalves WI Kourelis T Warsame R Russell SJ Lust JA Lin Y Go RS Zeldenrust S Kyle RA Rajkumar SV Kumar SK Gertz MA Depth of Organ Response in Newly Diagnosed AL Amyloidosis Is Associated with Improved Survival: Improved Outcome Discrimination with Graded Organ Response Blood 2017 130 Suppl 1 3154
68 Sanchorawala V Sun F Quillen K Sloan JM Berk JL Seldin DC Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience Blood 2015 126 20 2345 2347 https://doi.org/10.1182/blood-2015-08-662726 26443620 10.1182/blood-2015-08-662726
69 Gertz MA Lacy MQ Dispenzieri A Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis Bone Marrow Transplant 2013 48 4 557 561 https://doi.org/10.1038/bmt.2012.170 22964596 10.1038/bmt.2012.170
70 Dispenzieri A Buadi F Kumar SK Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement Mayo Clin Proc 2015 90 8 1054 1081 https://doi.org/10.1016/j.mayocp.2015.06.009 26250727 10.1016/j.mayocp.2015.06.009
71 Cibeira MT Sanchorawala V Seldin DC Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients Blood 2011 118 16 4346 4352 https://doi.org/10.1182/blood-2011-01-330738 21828140 10.1182/blood-2011-01-330738 PMC3204906
72 Landau H Smith M Landry C Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis Leukemia 2017 31 1 136 142 https://doi.org/10.1038/leu.2016.229 27560108 10.1038/leu.2016.229 PMC5220129
73 Hwa YL Kumar SK Gertz MA Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation Am J Hematol 2016 91 10 984 988 https://doi.org/10.1002/ajh.24453 27341539 10.1002/ajh.24453
74 Palladini G Perfetti V Obici L Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation Blood 2004 103 8 2936 2938 https://doi.org/10.1182/blood-2003-08-2788 15070667 10.1182/blood-2003-08-2788
75 Palladini G Russo P Nuvolone M Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis Blood 2007 110 2 787 788 https://doi.org/10.1182/blood-2007-02-076034 17606766 10.1182/blood-2007-02-076034
76 Palladini G Milani P Foli A Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach Haematologica 2014 99 4 743 750 https://doi.org/10.3324/haematol.2013.095463 24213149 10.3324/haematol.2013.095463 PMC3971085
77 Jaccard A Moreau P Leblond V High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis N Engl J Med 2007 357 11 1083 1093 https://doi.org/10.1056/NEJMoa070484 17855669 10.1056/NEJMoa070484
78 Kastritis E Wechalekar A Dimopoulos M Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis J Clin Oncol 2010 28 6 1031 1037 https://doi.org/10.1200/JCO.2009.23.8220 20085941 10.1200/JCO.2009.23.8220
79 Reece D Sanchorawala V Hegenbart U Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study Blood 2009 114 8 1489 1497 https://doi.org/10.1182/blood-2009-02-203398 19498019 10.1182/blood-2009-02-203398
80 Reece DE Hegenbart U Sanchorawala V Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study Blood 2011 118 4 865 873 https://doi.org/10.1182/blood-2011-02-334227 21562045 10.1182/blood-2011-02-334227
81 Reece DE Hegenbart U Sanchorawala V Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis Blood 2014 124 16 2498 2506 https://doi.org/10.1182/blood-2014-04-568329 25202139 10.1182/blood-2014-04-568329 PMC4199951
82 Palladini G Sachchithanantham S Milani P A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis Blood 2015 126 5 612 615 https://doi.org/10.1182/blood-2015-01-620302 25987656 10.1182/blood-2015-01-620302
83 Palladini G Milani P Foli A Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients Leukemia 2014 28 12 2311 2316 https://doi.org/10.1038/leu.2014.227 25059496 10.1038/leu.2014.227
84 Venner CP Gillmore JD Sachchithanantham S A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis Leukemia 2014 28 12 2304 2310 https://doi.org/10.1038/leu.2014.218 25027514 10.1038/leu.2014.218
85 Kastritis E Leleu X Arnulf B A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis Blood 2016 128 22
86 Kastritis E Gavriatopoulou M Roussou M Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib Blood Cancer J 2017 7 6 e570 https://doi.org/10.1038/bcj.2017.47 28622303 10.1038/bcj.2017.47 PMC5520394
87 Sidana S Tandon N Gertz MA Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis Bone Marrow Transplant 2017 https://doi.org/10.1038/s41409-017-0020-5 10.1038/s41409-017-0020-5 29269795
88 Palladini G Milani P Merlini G Novel strategies for the diagnosis and treatment of cardiac amyloidosis Expert review of cardiovascular therapy 2015 13 11 1195 1211 https://doi.org/10.1586/14779072.2015.1093936 26496239 10.1586/14779072.2015.1093936
89 Manwani R Foard D Mahmood S Rapid hematological responses improve outcomes in patients with very advanced (Stage IIIb) cardiac immunoglobulin light chain amyloidosis Haematologica 2018 https://doi.org/10.3324/haematol.2017.178095 29305414 10.3324/haematol.2017.178095 PMC5865426
90 Palladini G Milani P Foli A Presentation and outcome with second line treatment in AL amyloidosis previously sensitive to non-transplant therapies Blood 2017 10.1182/blood-2017-04-780544 29101236
91 Milani P Gertz MA Merlini G Dispenzieri A Attitudes about when and how to treat patients with AL amyloidosis: an international survey Amyloid 2017 1 4 https://doi.org/10.1080/13506129.2017.1370421 10.1080/13506129.2017.1370421 28857614
92 Tandon N Sidana S Gertz MA Treatment Patterns and Outcome Following Initial Relapse or Refractory Disease in Patients with Systemic Light Chain Amyloidosis Am J Hematol 2017 https://doi.org/10.1002/ajh.24723 10.1002/ajh.24723 28314084
93 Manwani R Hegenbart U Foard D Mahmood S Sachchithanantham S Yong K Popat R Kyriakou C Rabin N Fontana M Whelan C Lachmann H Lane T Quarta C Gillmore J Dittrich T Kimmich C Hawkins P Schönland S Wechalekar AD Safety and Efficacy of Deferred Autologous Stem Cell Transplantation in Patients with Systemic AL Amyloidosis with Significant Cardiac Involvement at Presentation Blood 2017 130 Suppl 1 1815
94 Dispenzieri A Lacy M Zeldenrust S The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis Blood 2007 109 2 465 470 https://doi.org/10.1182/blood-2006-07-032987 17008538 10.1182/blood-2006-07-032987
95 Sanchorawala V Wright D Rosenzweig M Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial Blood 2007 109 2 492 496 https://doi.org/10.1182/blood-2006-07-030544 16960148 10.1182/blood-2006-07-030544
96 Palladini G Russo P Foli A Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide Ann Hematol 2011 10.1007/s00277-011-1244-x 21533608
97 Kastritis E Terpos E Roussou M A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis Blood 2012 119 23 5384 5390 https://doi.org/10.1182/blood-2011-12-396903 22517904 10.1182/blood-2011-12-396903
98 Kumar SK Hayman SR Buadi FK Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial Blood 2012 119 21 4860 4867 https://doi.org/10.1182/blood-2012-01-407791 22504925 10.1182/blood-2012-01-407791 PMC3418771
99 Mahmood S Venner CP Sachchithanantham S Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens Br J Haematol 2014 166 6 842 848 https://doi.org/10.1111/bjh.12973 24930361 10.1111/bjh.12973
100 Specter R Sanchorawala V Seldin DC Kidney dysfunction during lenalidomide treatment for AL amyloidosis Nephrol Dial Transplant 2011 26 3 881 886 https://doi.org/10.1093/ndt/gfq482 20693160 10.1093/ndt/gfq482 PMC3108346
101 Moreau P Jaccard A Benboubker L Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study Blood 2010 116 23 4777 4782 https://doi.org/10.1182/blood-2010-07-294405 20724537 10.1182/blood-2010-07-294405
102 Sanchorawala V Patel JM Sloan JM Shelton AC Zeldis JB Seldin DC Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial Haematologica 2013 98 5 789 792 https://doi.org/10.3324/haematol.2012.075192 23144200 10.3324/haematol.2012.075192 PMC3640126
103 Cibeira MT Oriol A Lahuerta JJ A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis Br J Haematol 2015 170 6 804 813 https://doi.org/10.1111/bjh.13500 25974382 10.1111/bjh.13500
104 Hegenbart U Bochtler T Benner A Lenalidomide/ melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up Haematologica 2017 102 8 1424 1431 https://doi.org/10.3324/haematol.2016.163246 28522573 10.3324/haematol.2016.163246 PMC5541875
105 Dispenzieri A Buadi F Laumann K Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis Blood 2012 119 23 5397 5404 https://doi.org/10.1182/blood-2012-02-413161 22493299 10.1182/blood-2012-02-413161 PMC3369677
106 Sanchorawala V Shelton AC Lo S Varga C Sloan JM Seldin DC Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial Blood 2016 128 8 1059 1062 https://doi.org/10.1182/blood-2016-04-710822 27381904 10.1182/blood-2016-04-710822
107 Palladini G Milani P Foli A A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis Blood 2017 129 15 2120 2123 https://doi.org/10.1182/blood-2016-12-756528 28130212 10.1182/blood-2016-12-756528
108 Warsame R Laplant B Laumann K Kumar SK Gertz MA Kyle RA Lacy MQ Dingli D Leung N Buadi FK Hayman SR Kapoor P Hwa YL Fonder A Hobbs M Gonsalves WI Kourelis T Russell SJ Zeldenrust S Lin Y Muchtar E Go RS Rajkumar SV Dispenzieri A Long-Term Outcomes of IMiD Based Trials in Patients with Immunoglobulin Light Chain Amyloidosis (AL): A Pooled Analysis Blood 2017 130 Suppl 1 1833 10.1038/s41408-019-0266-9 PMC6949262 31913261
109 Cohen A Landau H Scott E Safety and Efficacy of Carfilzomib (CFZ) in Previously-Treated Systemic Light-Chain (AL) Amyloidosis Blood 2016 128 22
110 Sanchorawala V Palladini G Kukreti V A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis Blood 2017 130 5 597 605 https://doi.org/10.1182/blood-2017-03-771220 28550039 10.1182/blood-2017-03-771220 PMC6911836
111 Kaufman GP Schrier SL Lafayette RA Arai S Witteles RM Liedtke M Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis Blood 2017 https://doi.org/10.1182/blood-2017-01-763599 10.1182/blood-2017-01-763599 28615223
112 Sanchorawala V Sarosiek S Sloan JM Brauneis D Migre ME Mistark M Santos S Fennessey S Shelton AC Safety and Tolerability of Daratumumab in Patients with Relapsed Light Chain (AL) Amyloidosis: Preliminary Results of a Phase II Study Blood 2017 130 Suppl 1 507
113 Roussel M Stoppa A Perrot A Karlin L Arnulf B Macro M Huart A Frenzel L Morel P Boyle E Dorvaux V Merlini G Palladini G Lavergne D Bridoux F Jaccard A A Prospective Phase II of Daratumumab in Previously-Treated Systemic Light-Chain (AL) Amyloidosis Blood 2017 130 Suppl 1 508 10.1182/blood.2019004369 32108228
114 Merlini G Ascari E Amboldi N Interaction of the anthracycline 4′-iodo-4′-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis Proc Natl Acad Sci U S A 1995 92 7 2959 2963 https://doi.org/10.1073/pnas.92.7.2959 7708755 10.1073/pnas.92.7.2959 PMC42338
115 Merlini G Anesi E Garini P Treatment of AL amyloidosis with 4′-lodo-4′-deoxydoxorubicin: an update Blood 1999 93 3 1112 1113 10025983
116 Palha JA Ballinari D Amboldi N 4′-Iodo-4′-deoxydoxorubicin disrupts the fibrillar structure of transthyretin amyloid Am J Pathol 2000 156 6 1919 1925 https://doi.org/10.1016/S0002-9440(10)65065-1 10854215 10.1016/S0002-9440(10)65065-1 PMC1850080
117 Cardoso I Merlini G Saraiva MJ 4′-iodo-4′-deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters FASEB J 2003 17 8 803 809 https://doi.org/10.1096/fj.02-0764com 12724338 10.1096/fj.02-0764com
118 Gertz M Lacy M Dispenzieri A A multicenter phase II trial of 4′-iodo-4′deoxydoxorubicin (IDOX) in primary amyloidosis (AL) Amyloid 2002 9 1 24 30 https://doi.org/10.3109/13506120209072441 12000194 10.3109/13506120209072441
119 Cardoso I Saraiva MJ Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model FASEB J 2006 20 2 234 239 https://doi.org/10.1096/fj.05-4509com 16449795 10.1096/fj.05-4509com
120 Ward JE Ren R Toraldo G Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis Blood 2011 118 25 6610 6617 https://doi.org/10.1182/blood-2011-04-351643 21998211 10.1182/blood-2011-04-351643 PMC3242721
121 Wechalekar AD Whelan C Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis Blood Cancer J 2017 7 3 e546 28338670 10.1038/bcj.2017.26 PMC5380910 Edwards CV Gould J Langer AL Interim analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis Amyloid 2017 24 supp1 58 59 28434347 10.1080/13506129.2017.1292900
122 Ehrnhoefer DE Bieschke J Boeddrich A EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers Nat Struct Mol Biol 2008 15 6 558 566 https://doi.org/10.1038/nsmb.1437 18511942 10.1038/nsmb.1437
123 Hora M Carballo-Pacheco M Weber B Epigallocatechin-3-gallate preferentially induces aggregation of amyloidogenic immunoglobulin light chains Sci Rep 2017 7 41515 https://doi.org/10.1038/srep41515 28128355 10.1038/srep41515 PMC5269747
124 Hunstein W Epigallocathechin-3-gallate in AL amyloidosis: a new therapeutic option? Blood 2007 110 6 2216 https://doi.org/10.1182/blood-2007-05-089243 17785589 10.1182/blood-2007-05-089243
125 Mereles D Buss SJ Hardt SE Hunstein W Katus HA Effects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients with AL amyloidosis Clin Res Cardiol 2010 99 8 483 490 https://doi.org/10.1007/s00392-010-0142-x 20221615 10.1007/s00392-010-0142-x
126 Meshitsuka S Shingaki S Hotta M Phase 2 trial of daily, oral epigallocatechin gallate in patients with light-chain amyloidosis Int J Hematol 2017 105 3 295 308 https://doi.org/10.1007/s12185-016-2112-1 27815860 10.1007/s12185-016-2112-1
127 Pepys M Herbert J Hutchinson W Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis Nature 2002 417 6886 254 259 https://doi.org/10.1038/417254a 12015594 10.1038/417254a
128 Gillmore JD Tennent GA Hutchinson WL Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis Br J Haematol 2010 148 5 760 767 https://doi.org/10.1111/j.1365-2141.2009.08036.x 20064157 10.1111/j.1365-2141.2009.08036.x
129 Richards DB Cookson LM Berges AC Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component N Engl J Med 2015 373 12 1106 1114 https://doi.org/10.1056/NEJMoa1504942 26176329 10.1056/NEJMoa1504942
130 Edwards CV Gould J Langer AL Interim analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis Amyloid 2017 24 supp1 58 59 28434347 10.1080/13506129.2017.1292900
131 Edwards CV Gould J Langer AL Mapara MY Radhakrishnan J Maurer MS Raza S Mears JG Leng S Wall JS Eisenberger A Solomon A Lentzsch S Final Analysis of the Phase 1a/b Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients with Relapsed or Refractory AL Amyloidosis Blood 2017 130 Suppl 1 509
132 Gertz MA Landau H Comenzo RL First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction J Clin Oncol 2016 34 10 1097 1103 https://doi.org/10.1200/JCO.2015.63.6530 26858336 10.1200/JCO.2015.63.6530 PMC5470113
133 Gertz M Comenzo R Landau H Patients with light chain amyloidosis treated with neod001 achieve rapid organ responses that are independent of previous plasma cell-directed therapies Haematologica 2017 102 3 3
134 Bernardi L Passino C Porta C Anesi E Palladini G Merlini G Widespread cardiovascular autonomic dysfunction in primary amyloidosis: does spontaneous hyperventilation have a compensatory role against postural hypotension? Heart 2002 88 6 615 621 https://doi.org/10.1136/heart.88.6.615 12433892 10.1136/heart.88.6.615 PMC1767452
135 Caccialanza R Palladini G Klersy C Nutritional status of outpatients with systemic immunoglobulin light-chain amyloidosis American Journal of Clinical Nutrition 2006 83 2 350 354 16469994 10.1093/ajcn/83.2.350
136 Caccialanza R Palladini G Klersy C Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis Ann Hematol 2012 91 3 399 406 https://doi.org/10.1007/s00277-011-1309-x 21826471 10.1007/s00277-011-1309-x
137 Caccialanza R Palladini G Klersy C Malnutrition at diagnosis predicts mortality in patients with systemic immunoglobulin light-chain amyloidosis independently of cardiac stage and response to treatment JPEN J Parenter Enteral Nutr 2014 38 7 891 894 https://doi.org/10.1177/0148607113501328 24072737 10.1177/0148607113501328
138 Caccialanza R Palladini G Cereda E Nutritional counseling improves quality of life and preserves body weight in systemic immunoglobulin light-chain (AL) amyloidosis Nutrition 2015 31 10 1228 1234 https://doi.org/10.1016/j.nut.2015.04.011 26250487 10.1016/j.nut.2015.04.011
139 Kumar S Dispenzieri A Lacy MQ Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements J Clin Oncol 2012 30 9 989 995 https://doi.org/10.1200/JCO.2011.38.5724 22331953 10.1200/JCO.2011.38.5724 PMC3675680